N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Ovarian Hyperstimulation Syndrome
Primary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)
Phase 4 N=71 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Ovarian Hyperstimulation Syndrome
Primary: Ongoing Pregnancy — 15; 19 participants
N/A N=96 Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Vascular Endothelial Growth Factor Overexpression
Primary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
Phase 2 N=60 Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Endometriosis · Ovarian Hyperstimulation
Primary: Average Delta in Endometriosis Pain Score Pre and Post Stimulation With and Without Use Of Letrozole — -2.5; -2.7 Change in score on a scale
Phase 3 N=105 Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
Infertility
Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
Phase 3 N=176 A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes
Phase 3 N=900 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Phase 4 N=30 Continuous Double Ovarian Stimulation.
Fertility Issues
Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
Phase 4 N=110 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome · Infertility
Primary: Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 — 1; 0; 1; 0 Participants — p=1.000
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Phase 3 N=52 A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Infertility · Ovarian Stimulation
Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes
N/A N=20 Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
Mood
Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale
Phase 4 N=384 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
OHSS (Ovarian Hyperstimulation)
Primary: Frequency of Moderate to Severe OHSS. — 0; 2; 2; 0 participants
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 4 N=3 Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
Infertility
Primary: Fetal Heart Activity 1 Month After Oocyte Retrieval — 0; 0 participants with fetal heart activity
Phase 4 N=710 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
Infertility
Primary: Clinical Pregnancy Rate — 36.93; 39.66 percentage of participants — p=0.49
N/A N=11 IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing
Infertility
Primary: Fetal Heart Activity 1 Month Post Embryo Transfer — 0; 4 participants with fetal heart activity
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L